How do SGLT2 inhibitors fit into HF management?

• A. They have no effect on HF outcomes.
• B. They reduce HF hospitalizations and cardiovascular death in both HFrEF and HFpEF; beneficial across EF categories.
• C. They are only used for glycemic control in diabetics with HF and have no mortality benefit.
• D. They worsen renal function.

Answer: (B)

SGLT2 inhibitors are now a core part of heart failure management because they improve outcomes beyond glycemic control. Large trials show they reduce heart failure hospitalizations and cardiovascular death in patients with reduced ejection fraction and, more recently, in those with preserved ejection fraction as well—benefiting across different EF categories and even in people without diabetes.

Mechanistically, they help by promoting natriuresis and osmotic diuresis, which lowers preload and congestion. They also appear to improve myocardial energetics and reduce fibrosis, while providing kidney protection by lowering intraglomerular pressure and slowing the progression of kidney disease. This combination translates into fewer HF admissions and lower mortality risk, making them a standard part of guideline-directed HF therapy.

They are not limited to diabetics, and while they can cause an initial, small dip in kidney function or volume depletion in susceptible patients, the long-term renal benefits and overall HF outcomes are favorable with appropriate monitoring.